Knowledge graph · Drug
Teprotumumab
monoclonal antibody
- Identifier
- CI-DRUG-00000586
- Entity page
- /drug/teprotumumab ↗
- Edges
- 26
- Neighbours
- 8 cancers1 genes2 variants9 trials1 approvals
- Drawn
- 21 of 21 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Teprotumumab approved for …APPROVED_FORderived1 of 1 | ||||||||
| → approved for | FDA · US · 2020TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease ( 1 ) FDA (US) · approved · 2020-01-21 · TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin… | — | approved | not mapped | 1 | Regulatory | openfda | open ↗ |
| Teprotumumab … | ||||||||